Research and Development Investment: Eli Lilly and Company vs Takeda Pharmaceutical Company Limited

Eli Lilly vs Takeda: A Decade of R&D Investment

__timestampEli Lilly and CompanyTakeda Pharmaceutical Company Limited
Wednesday, January 1, 20144733600000382096000000
Thursday, January 1, 20154796400000345927000000
Friday, January 1, 20165243900000312303000000
Sunday, January 1, 20175281800000325441000000
Monday, January 1, 20185051200000368298000000
Tuesday, January 1, 20195595000000492381000000
Wednesday, January 1, 20206085700000455833000000
Friday, January 1, 20217025900000526087000000
Saturday, January 1, 20227190800000633325000000
Sunday, January 1, 20239313400000729924000000
Monday, January 1, 202414271000000729924000000
Loading chart...

Infusing magic into the data realm

A Decade of Innovation: R&D Investments in Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, Eli Lilly and Company and Takeda Pharmaceutical Company Limited have demonstrated contrasting strategies in their R&D expenditures.

Eli Lilly's R&D spending has seen a steady increase, growing by approximately 97% from 2014 to 2023. This reflects their commitment to pioneering new treatments and maintaining a competitive edge. In contrast, Takeda's R&D investments have been significantly higher, with a staggering 91% increase over the same period, highlighting their aggressive approach to expanding their research capabilities.

While Eli Lilly's R&D expenses reached a peak of $9.3 billion in 2023, Takeda's investments soared to $729 billion, showcasing their dominance in the sector. However, data for 2024 is incomplete, leaving room for speculation on future trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025